Channel Therapeutics News and Activities

Channel Therapeutics is owned by Ligand Pharmaceuticals.

Ligand Pharmaceuticals is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Ligand Pharmaceuticals is a company listed under the stock ticker LGND (US).

Ligand Pharmaceuticals has 3 subsidiaries including Captisol, Channel Therapeutics and Pelthos Therapeutics.

They are in:

• Pharmaceuticals50%
• Biotechnology50%

Acquisition, funding and merger involving Ligand Pharmaceuticals.

• The new name of Chromocell is Channel Therapeutics Corporation. (posted on November 22 2024).

View the org chart displaying its 4 main executives

Most searched biographies at Channel Therapeutics

• Frank Knuettel, Chief Executive Officer and Chief Financial Officer
• Richard Baxter, Director
• Scott Plesha, Director

Popular executive movements at Ligand Pharmaceuticals

• Peter Renehan has joined the company as Vice President, Investments and Business Development  (posted on April 3 2026).
• Lauren Hay who was Vice President, Strategic Planning and Investment Analytics, becomes Vice President of Portfolio Strategy and Investments  (posted on April 3 2026).
• Lee Brown has joined the company as Vice President, Investments & Business Development  (posted on April 3 2026).

Create your alert
to follow the executive moves at Channel Therapeutics.

Ligand Pharmaceuticals has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Channel Therapeutics

• Chromocell to Present at Upcoming Fall Investor Conferences
• Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain
• Chromocell Announces Amendment to Stock Repurchase Plan
• Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference
• Chromocell Announces Stock Repurchase Plan
• Chromocell to Participate in the Virtual Investor Lunch Break Series
• Alliance Global Partners Healthcare Company Showcase
• Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024
• Chromocell Issues Letter to Stockholders from Chief Executive Officer
• Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
• View more press releases Close

Social media about Channel Therapeutics

• Channel Therapeutics on Wikipedia, Google News & Yahoo Finance
• Channel Therapeutics on LinkedIn, X (Twitter) & YouTube